Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study

J Am Acad Dermatol. 2016 Jan;74(1):176-7. doi: 10.1016/j.jaad.2015.08.030.

Authors

Judy K Qiang¹, Ali Shahbaz², Whan Kim³, Joseph Marinas³, Simon Greaves⁴, Jensen Yeung⁵

Affiliations

¹ Faculty of Medicine, University of Toronto, Ontario, Canada.
² School of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
³ Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
⁴ Dalla Lana School of Public Health, University of Toronto, Ontario, Canada.
⁵ Divison of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

PMID: 26702799
DOI: 10.1016/j.jaad.2015.08.030

No abstract available

Publication types

Letter

MeSH terms

Academic Medical Centers
Adalimumab / therapeutic use
Adult
Aged
Biological Products / therapeutic use*
Canada
Cohort Studies
Dermatologic Agents / therapeutic use*
Drug Substitution / methods*
Etanercept / therapeutic use
Female
Follow-Up Studies
Humans
Infliximab / therapeutic use
Male
Middle Aged
Psoriasis / diagnosis
Psoriasis / drug therapy*
Retrospective Studies
Risk Assessment
Severity of Illness Index
Treatment Failure
Treatment Outcome
Ustekinumab / therapeutic use

Substances

Biological Products
Dermatologic Agents
Infliximab
Ustekinumab
Adalimumab
Etanercept